HISTOGENETICS

300 Executive Blvd, Ossining, New York - 10562.
Phone : 914-762-0300. Fax : 914-762-4441. Website : www.histogenetics.com
ASHI # 03-1-NY-26-2. CLIA # 33D0985173
Soo Young Yang Ph.D / Nezih Cereb M.D., Directors
Email : customerservice@histogenetics.com

ASHI ACCREDITED

HLA TYPING REPORT

Donor(s) Results

Last Name/URD#	: **NMDP**	Date Of Birth :	NA
First Name	: **195507918**	Histo ID :	H86661
Relation	: NA	Received On :	28-Feb-2020
Specimen Type	: Whole Blood	Collected On :	26-Feb-2020

A*	B*	C*	DRB1*	DRB345*	DQB1*	DQA1*	DPB1*	DPA1*
03:01:01G	**15:18:01G**	**07:04:01G**	**11:01:01G**	NA	**03:01:01G**	NA	NA	NA
68:01:01G	**52:01:01G**	**12:CAVPP**	**11:04:01**	NA	**03:01:01G**	NA	NA	NA

Typing Status : Complete

Null Allele Resolution Status : A*03:01:01:02N,A*03:21N,A*03:129N,A*03:162N,A*03:279N,A*03:336N,B*15:380N,B*15:487N,C*07:797N,DRB1*11:250N,DQB1*03:84N,DQB1*03:338N,DQB1*03:340N,DQB1*03:358N,DQB1*03:376N,DQB1*03:385N,DQB1*03:400N excluded

Note:

1. **Match ratio to Patient: Based on protein level in ARS (Exon 2 and 3 for Class I, Exon 2 for Class II).**

2. **Allele Database Version : 3.37.0 (Jul 2019)**

3. **Allele bearing suffix G : The first allele of the Included Alleles. Included alleles in the appendix**

4. **NMDP code is reported if G code is not available after analyzing non-ARS exons**

5. **Sequencing Technology : Illumina Sequencing**

6. **Reagent Information : Lot Number available upon request.**

Report History

Reported Date	History	Comments
02-Mar-2020	Donor: 195507918	

DIRECTOR / ASSOCIATE DIRECTOR *Nezih Cereb*

HLA TYPING REPORT - APPENDIX

Locus	G Code	NMDP Allele Code	Segment Sequenced	Included Alleles

Sample ID : H86661

Locus	G Code	NMDP Allele Code	Segment Sequenced	Included Alleles
A	03:01:01G	03:CAVHX	Exon 1,2,3,4	03:01:01:01/03:01:01:03/03:01:01:04/03:01:01:05/03:01:01:06/ 03:01:01:07/03:01:01:08/03:01:01:09/03:01:01:10/03:01:01:11/ 03:01:01:12/03:01:01:13/03:01:01:14/03:01:01:15/03:01:01:16/ 03:01:01:17/03:01:01:18/03:01:01:19/03:01:01:20/03:01:01:21/ 03:01:01:22/03:01:01:23/03:01:01:24/03:01:01:25/03:01:01:26/ 03:01:70/03:01:71/03:01:74/03:01:75/03:01:81/03:01:84/03:291/ 03:292/03:293/03:301/03:313/03:315/03:338/03:344/03:346/ 03:352/03:359/03:361/03:363/03:367
A	68:01:01G	68:CAVKN	Exon 1,2,3,4	68:01:01:01/68:01:01:02/68:01:01:03/68:188/68:211
B	15:18:01G	15:18:01	Exon 2,3,4	15:18:01:01/15:18:01:02/15:18:01:03/15:18:01:04/15:18:01:05
B	52:01:01G	52:CAVMU	Exon 2,3,4	52:01:01:01/52:01:01:02/52:01:01:03/52:01:01:04/52:01:01:05/ 52:01:01:06/52:01:30/52:01:36/52:01:38/52:01:44/52:53/52:79/ 52:90
C	07:04:01G	07:BKSYS	Exon 2,3,4,7	07:04:01:01/07:04:01:02/07:04:01:03/07:04:01:04/07:674/07:693
C	12:CAVPP	12:CAVPP	Exon 2,3,4,7	12:02:02:01/12:02:02:02/12:02:02:03/12:243/12:285
DQB1	03:01:01G	03:BMSUA	Exon 2,3	03:01:01:01/03:01:01:02/03:01:01:03/03:01:01:04/03:01:01:05/ 03:01:01:06/03:01:01:07/03:01:01:08/03:01:01:09/03:01:01:10/ 03:01:01:11/03:01:01:12/03:01:01:14/03:01:01:15/03:01:01:16/ 03:01:01:17/03:01:01:18/03:01:01:19/03:01:01:20/03:01:01:21Q/ 03:01:41/03:01:43/03:01:44/03:276N/03:292/03:293/03:294/ 03:297/03:326/03:342/03:350
DRB1	11:01:01G	11:01:01	Exon 2,3	11:01:01:01/11:01:01:02/11:01:01:03/11:01:01:04
DRB1	11:04:01		Exon 2,3	

DISCLAIMER: This test was developed in and its performance characteristics determined by Histogenetics. It has not been cleared or approved by the U.S. FDA.